Breast Cancer

ASCO 2025 Highlights: Dr. Rebecca Shatsky on Evolving Therapies in HR+ Breast Cancer

Rebecca Shatsky, MDHR Breast Cancer | June 18, 2025

New drugs like vepdegestrant and oral SERDs may reshape HR+ breast cancer treatment with novel mechanisms and CDK4/6 combos.

Clinical Trial Gaps in TNBC: New Data Underscores Access Inequities for Black Women

David M. Waterhouse, MD, MPHTriple-Negative Breast Cancer | June 17, 2025

Dr. David Waterhouse discusses geographic barriers to TNBC trials for Black women and the case for decentralized research.

How DESTINY-Breast09 Could Reshape HER2+ mBC Care: Insights From Dr. Sibylle Loibl

Sibylle Loibl, MDHER2 Breast Cancer | June 18, 2025

DESTINY-Breast09 shows promising PFS with T-DXd + pertuzumab vs THP in HER2+ MBC, but safety and sequencing raise questions.

Neoadjuvant Immunity: Oncolytic Virus + Chemo Shows Promise in Early TNBC

Hatem Soliman, MDTriple-Negative Breast Cancer | June 12, 2025

TVEC plus chemo shows promise in early TNBC, boosting immune response and survival with favorable safety profile.

How AI Is Reshaping Oncology Practice: Insights From ASCO’s AI Task Force

Debra Patt, MD, PhD, MBABreast Cancer News | June 12, 2025

Dr. Patt discusses how AI is transforming oncology care, and how to implement it responsibly and effectively.

ReDiscover Trial: Novel PI3Kα Inhibitor RLY-2608 Shows Promising Safety, Efficacy

Sarah Sammons, MDHR Breast Cancer | June 12, 2025

Dr. Sammons on RLY-2608 plus fulvestrant in HR+/HER2– mBC with PIK3CA mutations: safety, efficacy, and trial updates.

HER2+ Practice-Changing Data From ASCO 2025 With Dr. Rebecca Shatsky

Rebecca Shatsky, MDHER2 Breast Cancer | June 10, 2025

Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.

Emi-Le ADC Targets B7-H4 in TNBC and Beyond: Promising Early Efficacy with Novel Payload

Erika P. Hamilton, MDTriple-Negative Breast Cancer | June 9, 2025

Emi-Le ADC shows promising activity in B7-H4–positive TNBC and endometrial cancer with a novel auristatin payload.

Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial

Sibylle Loibl, MDHR Breast Cancer | June 9, 2025

INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.

Can We Improve Second-Line Outcomes in ESR1-Mutated mBC? Insights From ADELA

Antonio Llombart Cussac, MD, PhDHR Breast Cancer | June 11, 2025

ADELA trial explores elacestrant + everolimus for ESR1-mutated breast cancer post-CDK4/6, aiming to boost 2L outcomes.

Expert Interviews on Oncology

DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.

Get the latest medical updates and insights straight to your inbox.

Section Editor

Dr. Sadie Dobrozsi, EvolentHematologist/oncologist and Medical Director, Evolent